Evrópusambandið - lettneska - EMA (European Medicines Agency)

pfizer europe ma eeig - pegvizomants - akromegālija - hipofīzes un hipotalāma hormoni un analogi - Ārstēšana pieaugušiem pacientiem ar akromegālijas, kas ir bijusi neatbilstoša atbildreakcija uz operācijas un/vai staru terapiju un kuram atbilstošu ārstēšanu ar somatostatin analogi nav normalizē igf-i koncentrācijas vai nav pieļauta. Ārstēšana pieaugušiem pacientiem ar akromegālijas, kas ir bijusi neatbilstoša atbildreakcija uz operācijas un/vai staru terapiju un kuram atbilstošu ārstēšanu ar somatostatin analogi nav normalizē igf-i koncentrācijas vai nav pieļauta.

Evrópusambandið - lettneska - EMA (European Medicines Agency)

roche registration gmbh - atezolizumabs - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastiski līdzekļi - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kā monotherapy ir norādīts ārstēšanai pieaugušiem pacientiem ar lokāli papildu vai metastātiska nsclc pēc iepriekšējas ķīmijterapijas. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kā monotherapy ir norādīts ārstēšanai pieaugušiem pacientiem ar lokāli papildu vai metastātiska nsclc pēc iepriekšējas ķīmijterapijas. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Evrópusambandið - lettneska - EMA (European Medicines Agency)

roche registration limited - emicizumabs - a hemofīlija - antihemorāģija - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra var izmantot visās vecuma grupās.

Evrópusambandið - lettneska - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multiple mieloma - antineoplastiski līdzekļi - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Lettland - lettneska - Zāļu valsts aģentūra

orpha-devel handels und vertriebs gmbh, austria - esmolola hidrohlorīds - Šķīdums injekcijām - 100 mg/10 ml

Lettland - lettneska - Zāļu valsts aģentūra

orpha-devel handels und vertriebs gmbh, austria - esmolola hidrohlorīds - pulveris infūziju šķīduma koncentrāta pagatavošanai - 2500 mg

Lettland - lettneska - Zāļu valsts aģentūra

sandoz d.d., slovenia - atorvastatīns - apvalkotā tablete - 20 mg

Lettland - lettneska - Zāļu valsts aģentūra

sandoz d.d., slovenia - atorvastatīns - apvalkotā tablete - 10 mg

Lettland - lettneska - Zāļu valsts aģentūra

novartis baltics, sia, latvia - dexamethasonum, neomycini sulfas, polymyxini b sulfas - acu pilieni, suspensija - 1 mg/3500sv/6000 sv/ml

Evrópusambandið - lettneska - EMA (European Medicines Agency)

astellas pharma europe b.v. - micafungin - candidiasis - antimycotics sistēmiskai lietošanai - mycamine ir norādīts:pieaugušajiem, pusaudžiem no 16 gadu vecuma un elderlytreatment invazīvo kandidoze;ārstēšana barības kandidozes pacientiem, kuriem intravenozo terapiju, ir atbilstošas;profilakse candida infekcijas pacientiem, kam veic alogēnas hematopoētisko cilmes šūnu transplantācijas, vai pacientiem, kam ir paredzēts neutropenia (absolūtais neitrofīlu skaits < 500 šūnas/µl), 10 vai vairāk dienas. bērniem (arī jaundzimušajiem) un pusaudžiem līdz 16 gadu agetreatment invazīvo kandidoze. profilakses candida infekcijas pacientiem, kam veic alogēnas hematopoētisko cilmes šūnu transplantācijas, vai pacientiem, kam ir paredzēts neutropenia (absolūtais neitrofīlu skaits < 500 šūnas/µl), 10 vai vairāk dienas. lēmums izmantot mycamine, būtu jāņem vērā risks, attīstības aknu audzēji. mycamine vajadzētu izmantot tikai tad, ja citi pretsēnīšu nav piemērota.